Sunday, November 28th, 2021


A full text version of this article is available.
To access article obtain online access here or login
Effect of Intracoronary Application of Nicorandil and Tirofiban on No-Reflow Phenomenon in Patients with Acute Coronary Syndrome
Authors:  Feng Yan, M.M., Qian Wang, M.M., Junnan Li, M.M., and Hui Lv, M.D.
  Objective: To investigate the effects of nicorandil and tirofiban on no-reflow and postoperative outcome in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention.
Study Design:
A total of 438 patients with ACS diagnosed by the second Hospital of Shanxi Medical University from January 2019 to December 2020 were divided into two groups: nicorandil group (n=223) and tirofiban group (n=215). The nicorandil group was injected with 2 mg nicorandil 2 mm before coronary occlusion before balloon dilation, and the tirofiban group received 10 μg/kg intravenous injection during operation. Measurement of thrombolysis grade (thrombolysis in myocardial infarction [TIMI]), corrected TIMI frame count, and major adverse vascular events were recorded 30 days after operation in patients with ACS.
Both nicorandil and tirofiban could improve the TIMI grade, and TIMI grade 3 blood flow was obtained in 190 cases (85.2%) and 175 cases (81.4%), respectively. There was no significant difference in the incidence of major adverse cardiac events (14.3% vs. 13.5%, score 0.13).
Intracoronary use of nicorandil in patients with ACS can improve coronary perfusion, but the improvement of prognosis needs further study.
Keywords:  coronary perfusion, myocardial infarction, nicorandil, no-reflow phenomenon, percutaneous coronary intervention, repercussion
  Acrobat Reader 7.0 is recommended to properly view and print the article.
Reader can be downloaded from